on EUROBIO-SCIENTIFIC (EPA:ALERS)
Eurobio Scientific Completes Acquisition of EndoPredict® Genomic Test from Myriad Genetics
Paris, August 2nd, 2024 – Eurobio Scientific, a French group specializing in in vitro medical diagnostics and life sciences, has finalized the acquisition of the EndoPredict® genomic test from Myriad Genetics. This test is designed for breast cancer diagnostics.
The agreement, initially announced on May 7, 2024, also includes a license to distribute the Prolaris® genomic test for prostate cancer. The combined annual revenue from these activities is approximately €8 million. However, short to medium-term EBITDA levels are expected to dilute the Group’s performance.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROBIO-SCIENTIFIC news